Sarepta and Roche aim to resume paused Elevidys trials following patient death

Sarepta Therapeutics and Roche are looking to get approval to continue clinical trials of their Duchenne muscular dystrophy gene therapy Elevidys (delandistrogene moxeparvovec-rokl) following a review prompted by a patient death.